Tumorigenic potential and disease manifestations of malignant B-cell variants differing in their fibronectin adhesiveness

Ramiro, 2006, Switching on chromosomal translocations, Cancer Res, 66, 7837, 10.1158/0008-5472.CAN-06-0863 Gonzalez, 2007, Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma, Blood, 110, 3112, 10.1182/blood-2007-02-069625 Epeldegui, 2006, Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B cell activation-associated molecular lesions, Curr Opin Oncol, 18, 444, 10.1097/01.cco.0000239882.23839.e5 Young, 2004, Epstein-Barr virus: 40 years on, Nat Rev Cancer, 4, 757, 10.1038/nrc1452 Kuppers, 2005, Mechanisms of B-cell lymphoma pathogenesis, Nat Rev Cancer, 5, 251, 10.1038/nrc1589 Munk Pedersen, 2004, Microenvironmental interactions and survival of CLL, B-cells. Leuk Lymphoma, 45, 2365, 10.1080/10428190412331272703 Mitsiades, 2006, The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions, Eur J Cancer, 42, 1564, 10.1016/j.ejca.2005.12.025 Pagnucco, 2004, Targeting multiple myeloma cells and their bone marrow microenvironment, Ann N Y Acad Sci, 1028, 390, 10.1196/annals.1322.047 Roccaro, 2006, Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells, Cancer Res, 66, 184, 10.1158/0008-5472.CAN-05-1195 Ng, 2002, Death associated protein kinase: from regulation of apoptosis to tumor suppressive functions and B cell malignancies, Apoptosis, 7, 261, 10.1023/A:1015364104672 Ria, 2002, Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma, Haematologica, 87, 836 Garcia-Gila, 2002, Adhesion to fibronectin via alpha4 integrin (CD49d) protects B cells from apoptosis induced by serum deprivation but not via IgM or Fas/Apo-1 receptors, Clin Exp Immunol, 127, 455, 10.1046/j.1365-2249.2002.01787.x Hazlehurst, 2001, Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies, Cancer Metastasis Rev, 20, 43, 10.1023/A:1013156407224 Lengauer, 1998, Genetic instabilities in human cancers, Nature, 396, 643, 10.1038/25292 Yang, 2005, Prognostic significance of clonal diversity of immunoglobulin gene rearrangements in patients with diffuse large B-cell lymphoma, Oncol Rep, 13, 503 Nadav, 2006, The generation and regulation of functional diversity of malignant plasma cells, Cancer Res, 66, 8608, 10.1158/0008-5472.CAN-06-1301 Zhu, 2002, V(H) gene analysis of splenic marginal zone lymphomas reveals diversity in mutational status and initiation of somatic mutation in vivo, Blood, 100, 2659, 10.1182/blood-2002-01-0169 Kalchenko, 2006, Use of lipophilic near-infrared dye in whole-body optical imaging of hematopoietic cell homing, J Biomed Opt, 11, 10.1117/1.2364903 Damiano, 1999, Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines, Blood, 93, 1658, 10.1182/blood.V93.5.1658 Redondo-Munoz, 2006, MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration, Blood, 108, 3143, 10.1182/blood-2006-03-007294 de la Fuente, 2002, Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine, J Leukoc Biol, 71, 495, 10.1189/jlb.71.3.495 Huang, 1993, Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease, Cancer Res, 53, 1392 Corre, 2007, Bone marrow mesenchymal stem cells are abnormal in multiple myeloma, Leukemia, 21, 1079, 10.1038/sj.leu.2404621 Perez, 2008, Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP, J Immunol, 180, 1545, 10.4049/jimmunol.180.3.1545 Hecht, 2008, Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA), Exp Cell Res, 314, 1082, 10.1016/j.yexcr.2007.10.021 Vande Broek, 2008, Extravasation and homing mechanisms in multiple myeloma, Clin Exp Metastasis, 25, 325, 10.1007/s10585-007-9108-4 Vanderkerken, 2000, Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse, Br J Cancer, 82, 953, 10.1054/bjoc.1999.1024 Dhodapkar, 1998, Biologic and therapeutic determinants of bone mineral density in multiple myeloma, Leuk Lymphoma, 32, 121, 10.3109/10428199809059252 Abildgaard, 2004, Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma, Haematologica, 89, 567 Teoh, 1997, Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma, Hematol Oncol Clin North Am, 11, 27, 10.1016/S0889-8588(05)70413-5 Silvestris, 2006, In-vitro functional phenotypes of plasma cell lines from patients with multiple myeloma, Leuk Lymphoma, 47, 1921, 10.1080/10428190600649521 Weinstat-Saslow, 1994, Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis, Cancer Res, 54, 6504 Rak, 1993, Growth advantage (“clonal dominance”) of metastatically competent tumor cell variants expressed under selective two- or three-dimensional tissue culture conditions, In Vitro Cell Dev Biol Anim, 29A, 742, 10.1007/BF02631431 Mori, 2004, Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis, Blood, 104, 2149, 10.1182/blood-2004-01-0236 Damiano, 2002, Integrins as novel drug targets for overcoming innate drug resistance, Curr Cancer Drug Targets, 2, 37, 10.2174/1568009023334033